GRAIL, Inc. (GRAL) Stock Analysis
Last updated Sep 8, 2026
Health Check
Last analyzed Sep 7, 2026
- Financial Health 55
- Profitability 60
- Business Quality 50
- Balance Sheet 55
- Cash Flow 25
Why this rating?
Health 52/100 — Acceptable
Entry timing is weak right now. Quality may be fine; the setup is not.
Company overview
GRAIL, Inc. (GRAL) is a Diagnostics & Research company in the Healthcare sector. Compound Radar rates GRAIL, Inc. 52/100 (Acceptable) due to solid business quality and strong revenue growth.
Investment profile
- Quality Moderate
- Growth Strong
- Balance Sheet Unknown
Financial highlights
Valuation
- Forward P/E -8.01
- EV/Revenue 17.05
Profitability
- Revenue Growth 25.7%
- Gross Margin 49.7%
- Operating Margin -332.0%
- Net Margin -236.9%
- ROE -16.1%
Financial strength
- Cash $861.61M
- Debt $91.31M
- Net Cash $770.30M
- Free Cash Flow $-299.92M
- Current Ratio 10.95
Similar companies
Peers in Diagnostics & Research, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Veracyte, Inc. Diagnostics & Research VCYT$42.45 82 Health 82 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Illumina, Inc. Diagnostics & Research ILMN$211.06 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- CareDx, Inc. Diagnostics & Research CDNA$50.31 73 Health 73 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Qiagen N.V. Diagnostics & Research QGEN$42.38 71 Health 71 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Danaher Corporation Diagnostics & Research DHR$205.23 68 Health 68 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Quest Diagnostics Incorporated Diagnostics & Research DGX$235.50 67 Health 67 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Sotera Health Company Diagnostics & Research SHC$18.59 67 Health 67 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Revvity, Inc. Diagnostics & Research RVTY$127.08 66 Health 66 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks GRAIL, Inc. (GRAL).